**Telomerase activity assay for the diagnosis of malignant pleural effusion: A meta-analysis**

YONG-CHUN SHEN¹*, ZHEN-NI CHEN²*, TING YANG¹, LEI CHEN¹, TAO WANG¹, FU-QIANG WEN¹ and QUN YI¹

¹Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Department of Respiratory Medicine, West China Hospital of Sichuan University; ²Department of Health Education Institution, West China School of Public Health, Chengdu, Sichuan 610041, P.R. China

Received April 4, 2012; Accepted June 6, 2012

DOI: 10.3892/etm.2012.623

**Abstract.** The telomerase activity assay has been established for the detection of malignant pleural effusion (MPE), however, the overall diagnostic accuracy of the telomerase activity assay for MPE remains unclear. We performed a systematic search in the Pubmed, Embase and Cochrane databases to identify published studies that have evaluated the diagnostic role of the telomerase activity assay for MPE. Sensitivity, specificity and other measures of accuracy of the telomerase activity assay in the diagnosis of MPE were pooled using the random effects models. A summary receiver operating characteristic (SROC) curve was used to summarize overall test performance. A total of eight studies met the inclusion criteria for the meta-analysis. The pooled sensitivity and specificity for diagnosing MPE were 0.76 [95% confidence intervals (CI), 0.72-0.80] and 0.87 (95% CI, 0.83-0.91), respectively. The positive likelihood ratio was 5.19 (95% CI, 2.36-11.42), the negative likelihood ratio was 0.25 (95% CI, 0.11-0.53) and the diagnostic odds ratio was 23.18 (95% CI, 6.11-87.83). The area under the SROC curve was 0.92. The telomerase activity assay plays a role in the diagnosis of MPE with a relatively high specificity. The results of a telomerase activity assay should be interpreted together with the combination of other test results and clinical findings.

**Introduction**

Pleural effusion is a frequent complication in patients with cardiac failure, pneumonia, tuberculosis and neoplasms (1). Malignancy is one of the most significant causes of pleural effusion and more than 90% of malignant pleural effusions (MPEs) are caused by metastatic diseases (2). It is necessary to elucidate their etiologies, yet to differentiate MPE from benign pleural effusion remains a clinical challenge (3). Initial diagnostic methods include cytological, histological, biochemical and thoracocentesis examinations. However, the overall sensitivity of cytological examination is only 60% (3), thoracoscopic pleural biopsy or image-guided percutaneous pleural biopsy provides a relative high sensitivity, but may not be available in all hospitals or well-tolerated (4).

A series of tumor markers have been well-studied for their ability to improve the diagnosis of MPE. Three published studies have investigated the diagnostic value of the pleural vascular endothelial growth factor, carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125, 15-3 and 19-9, and CYFRA 21-1 in MPE but have failed to identify a reliable tumor marker with both high sensitivity and high specificity. The authors did not recommend using one tumor marker alone for the diagnosis of MPE (5-7). Therefore it is imperative to find a new diagnostic tool to facilitate diagnostic accuracy.

Telomerase is a specialized reverse transcriptase that adds TTAGGG repeats to the telomeric ends of chromosomal DNA to maintain the telomeric length (8). The expression of telomerase activity has been shown to be correlated with telomeric length (9). Telomerase is active in many types of human cancers but is not detectable in most normal somatic cells (10,11). Therefore telomerase activity may be a universal and specific marker for diagnosing a wide variety of cancers (12). Several studies have shown that the measurement of telomerase activity may be a useful and noninvasive method to detect malignancy in body fluid, particularly when used in combination with conventional cytological examination (13,14). A number of studies on the potential diagnostic role of telomerase activity assay in MPE have been published and have reported varying results. The present meta-analysis aimed to establish the overall accuracy of the telomerase activity assay in the diagnosis of MPE.

**Materials and methods**

**Meta-analysis.** The present meta-analysis was performed according to the guidelines of the Preferred Reporting Items
for Systematic Reviews and Meta-Analysis (PRISMA) statement and with methods recommended by the Cochrane Diagnostic Test Accuracy Working Group (15,16).

Search strategy and study selection. To identify studies that have evaluated the evidence of using telomerase activity in order to diagnose MPE, we performed a search of the Pubmed (Medline), Embase and Cochrane databases up to March 15, 2012, using the key words ‘pleural effusion’, ‘malignant pleural effusions’ and ‘telomerase activity’. Although no language restrictions were imposed on the search criteria, only English- and Chinese-language publications concerning human studies were included in the present meta-analysis. In addition, a manual search of the reference lists of eligible papers was also conducted.

Conference abstracts were excluded due to the limited data provided. A study was included in the present meta-analysis if it provided data on both sensitivity and specificity of pleural telomerase activity for the diagnosis of MPE. Studies with fewer than 10 patients were excluded to avoid selection bias. Two authors (Y-C Shen and Z-N Chen) independently screened the articles for inclusion. Disagreements between authors were resolved by consensus.

Data extraction and quality assessment. The final set of articles was assessed independently by two reviewers (Y-C Shen and Z-N Chen). The data retrieved from the reports included author, publication year, patient source, test method, sensitivity and specificity data, and methodological quality. When the same patients were reported in several studies, only the most informative article was included to avoid duplication of information. The methodological quality of studies was evaluated by a QUADAS tool (Quality Assessment for Studies of Diagnostic Accuracy, an evidence based quality assessment tool to be used in systematic reviews of diagnostic accuracy studies, maximum score 14) (17).

Statistical analyses. The standard methods recommended for the meta-analyses of diagnostic accuracy studies were used in the present study (18). The following measures of test accuracy were calculated for each study: sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR), together with their 95% confidence interval (CI). The present meta-analysis was based on a summary receiver operating characteristic (SROC) curve, and the sensitivity and specificity for the single test threshold identified for each study was used to plot an SROC curve (19). A random-effects meta-analysis was performed in order to account for the differences between study variability for each study. The Spearman's rank correlation was performed as a test for threshold effect. Chi-squared and Fisher's exact tests were used to detect statistically significant heterogeneity across studies. Since publication bias is of concern for meta-analyses of diagnostic studies, we tested for the potential presence of this bias using Deeks funnel plots (20). All analyses were performed using two statistical software programs (Meta-DiSc for Windows; XI Cochrane Colloquium, Barcelona, Spain and Stata, version 11; Stata Corporation, College Station, TX, USA). All statistical tests were two-sided and P<0.05 was considered to indicate a statistically significant result.

Results

Study exclusion criteria. After independent review, eight studies with 678 samples on the use of telomerase activity in patients with MPE were considered eligible for inclusion in the present meta-analysis (21-28). The major reasons for excluding the other studies were as follows: non-diagnostic studies or studies cannot reconstruct the diagnostic 2 by 2 table; limited samples, or mixed with other serous effusions and duplicated studies. The clinical summary of these studies, along with the QUADAS scores, are outlined in Table I.

Study characteristics and quality report. There were five English and three Chinese articles. The average sample size in the eight studies was 85 (range from 28 to 144) and the samples included 375 patients with MPE and 303 non-MPE. Telomerase activity was measured by a PCR-based or PCR-ELISA method. The current gold standards, cytological
and histological examinations, are highly reliable methods to identify MPE. The quality of the eight studies was generally high with six studies having QUADAS scores ≥10.

Diagnostic accuracy for MPE. The heterogeneity analysis revealed I²-values of 91.5% for sensitivity and 67.1% for specificity. The existence of significant heterogeneity occurred in the eight studies, thus the random effects model approach was selected for the present meta-analysis. The forest plots of the sensitivity and specificity for eight telomerase activity assays in diagnosing MPE are shown in Figs. 1 and 2, respectively. The pooled sensitivity was 0.76 (95% CI, 0.72-0.80), specificity was 0.87 (95% CI, 0.83-0.91). The PLR was 5.19 (95% CI, 2.36-11.42), the NLR was 0.25 (95% CI, 0.11-0.53) and the DOR was 23.18 (95% CI, 6.11-87.83).

The SROC curve plotting the true-positive against the false-positive rates of individual studies is shown in Fig. 3. The area under curve (AUC) was 0.92, indicating that the level of overall accuracy was high.

Publication bias. The Deeks funnel plot asymmetry test was used to evaluate potential publication bias; the statistically insignificant value (P=0.73) for the slope coefficient suggests symmetry in the data and a low likelihood of publication bias (Fig. 4).

In addition, we did not perform a meta-regression analysis with QUADAS scores to assess the effect of study quality on relative DOR of telomerase activity in the diagnosis of MPE due to the limited numbers of studies included. For the same reason, we could not explore whether or not the study design including blinded, cross-sectional, consecutive/random and prospective design affected diagnostic accuracy.

Discussion

The present meta-analysis evaluated the overall diagnostic role of pleural telomerase activity in MPE. To the best of our knowledge, this is the first meta-analysis to assess the diagnostic role of telomerase activity in MPE. We found a summary AUC of 0.92, a summary estimate of 0.76 for sensitivity and 0.87 for specificity. It appears that telomerase activity examination plays a valuable role in the diagnosis of MPE. It may be more favor in confirming MPE.

The SROC curve has been recommended to represent the performance of a diagnostic test, and shows the trade-off between sensitivity and specificity based on data from a meta-analysis (29,30). The AUC and an index Q’ are recognized as potentially useful summaries of the curve. We used the Q-value, intersection point of the SROC curve with a diagonal line from the left upper corner to the right lower...
corner of the ROC space, which corresponds to the highest common value of sensitivity and specificity for the test and represents an overall measure of the discriminatory power of a test. In the present study, the Q-value was 0.86, demonstrating that the maximum joint sensitivity and specificity was 0.86. The AUC also measures the overall accuracy of diagnostic studies. If the AUC is 1, then the telomerase activity test differentiates perfectly between MPE and non-MPE subjects. An AUC of greater than 0.9 indicates high diagnostic accuracy. In our meta-analysis, the AUC was 0.92, suggesting the level of overall accuracy was high.

The DOR is a single indicator of test accuracy that combines the data from sensitivity and specificity into a single number (31). It is the ratio of the odds of positive test results in the diseased, relative to the odds of positive test results in the non-diseased. The value of a DOR ranges from 0 to infinity, with higher values indicating an improved discriminatory test performance. In the present meta-analysis, the mean DOR was 23.18, suggesting that the telomerase activity assays appeared to be useful in the diagnosis of MPE. Since the SROC curve and DOR are not easy to interpret and use in clinical practice, likelihood ratios are considered more clinically meaningful (32). The PLR was 5.19, indicating that patients with MPE have an approximate 5-fold higher chance of being telomerase activity assay-positive compared with patients without MPE. However, the PLR was not high enough for making a definitive clinical decision. The NLR was found to be 0.25, which means if the telomerase activity assay result was negative, the probability that this patient has MPE is 25%, which is not low enough to exclude MPE.

Our meta-analysis suggests that telomerase activity determination plays a valuable role in diagnosing MPE, especially in the confirmation of MPE. The reported sensitivities varied among studies, ranging from 0.32 to 1.00. As Lee (24) suggested that the ELISA-based telomerase activity assay is relatively insensitive, it is unsuitable as a routine screening tool for MPE. False-positive telomerase activity due to lymphocytic contamination may weaken the diagnostic value for MPE in a tuberculosis-endemic area (24). The combination with other markers for pleural effusion would aid in increasing the sensitivity. For instance, the combination of telomerase activity with CEA or CYFRA21-1 was found to provide a high sensitivity of 0.93 and 0.90, respectively (26,28). The further development of the method of telomerase activity measure-
ment may increase diagnostic accuracy for MPE. Hansson et al (33) reported that telomerase activity measurement in situ based on cytopsins from fresh cytological material correlated well to final diagnoses and could differentiate between MPE and non-MPE cases. It was suggested that this method may improve the diagnostic accuracy for MPE (33,34). Cytological and/or histological examinations remain the traditional method for diagnosing MPE, however, pathologists do not recommend a diagnosis solely based on cytological samples due to the high risk of diagnostic error. In addition, the invasive thoracoscopy may not be available in all hospitals (3,4). Thus, the importance of the telomerase activity test is not only to provide high specificity with which to confirm the diagnosis of MPE, but also to guide the inclusion of patients who may benefit from further invasive procedures.

The present meta-analysis had several limitations. Although we strengthened the present meta-analysis comprehensive search strategy and data extraction, only eight studies with 678 samples were included. The evidence generated from the limited studies and samples may limit the interpretation of the meta-analysis results. Secondly, we excluded conference abstracts and non-English or non-Chinese publications, which may have led to publication bias (35), which may also be introduced by inflation of diagnostic accuracy estimates since studies that report positive findings are more likely to be accepted for publication. However, there was no publication bias reported in the present meta-analysis due to the limited number of studies included. We did not use QUADAS scores to perform the meta-regression analysis or explore whether or not the study design affected diagnostic accuracy.

Based on the evidence compiled in this meta-analysis, telomerase activity measurement plays a role in the diagnosis of MPE, and it is likely to be a useful diagnostic tool for confirming MPE. The results of telomerase activity assays should be interpreted in parallel with clinical findings and the results of conventional tests. Studies with larger sample sizes and improved telomerase activity examination methods are still required to determine the diagnostic performance of the telomerase activity assay for MPE.

Acknowledgements

This work is supported by grants 30971327 and 31171103 from the National Natural Science Foundation of China and grants 00-722 and 06-834 from the China Medical Board of New York to Dr Fu-Qiang Wen.

References

1. Light RW: Pleural effusions. Med Clin North Am 95: 1055-1070, 2011.
2. Bennett R and Maskell N: Management of malignant pleural effusions. Curr Opin Pulm Med 11: 296-300, 2005.
3. McGrath EE and Anderson PB: Diagnosis of pleural effusion: a systematic approach. Am J Crit Care 20: 119-127, 2011.
4. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Artioli G and Pastorelli D: Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol 33: 420-423, 2010.
5. Shen YC, Liu MQ, Wan C, Chen L, Wang T and Wen FQ: Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion. Exp Ther Med: March 14, 2012 (Epub ahead of print).
6. Shi HZ, Liang QL, Jiang J, Qin XJ and Yang HB: Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respiriology 13: 518-527, 2008.
7. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J and Yang HB: Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax 63: 35-41, 2008.
8. Zvereva MI, Shcherbakova DM and Dontsova OA: Telomerase: structure, functions, and activity regulation. Biochemistry (Mosc) 75: 1563-1583, 2010.
9. Rhyu MS: Telomeres, telomerase, and immortality. J Natl Cancer Inst 87: 884-894, 1995.
10. Chen CH and Chen RJ: Prevalence of telomerase activity in human cancer. J Formos Med Assoc 110: 275-289, 2011.
11. Ouellette MM, Wright WE and Shaw JY: Targeting telomerase-expressing cancer cells. J Cell Mol Med 15: 1433-1442, 2011.
12. Heaphy CM and Meeker AK: The potential utility of telomere-related markers for cancer diagnosis. J Cell Mol Med 15: 1227-1238, 2011.
13. Tangkijvanich P, Tresukosol D, Sampatpanukul P, et al: Telomerase assay for differentiating between malignancy-related and nonmalignant ascites. Clin Cancer Res 5: 2470-2475, 1999.
14. Braunischweig R, Yan P, Guillereit L, et al: Detection of malignant effusions: comparison of a telomerase assay and cytologic examination. Diagn Cytopathol 24: 174-180, 2001.
15. Moller D, Liberati A, Tetzlaff J and Altman DG: PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097, 2009.
16. Leeflang MM, Deeks JJ, Gatsonis C and Bossuyt PM: Cochrane Diagnostic Test Accuracy Working Group: Systematic reviews of diagnostic test accuracy. Ann Intern Med 149: 889-897, 2008.
17. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN and Kleijnen J: Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 6: 9, 2006.
18. Devillé WL, Buntinx F, Bouter LM, et al: Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2: 9, 2002.
19. Moses LE, Shapiro D and Littenberg B: Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12: 1293-1316, 1993.
20. Deeks JJ, Macaskill P and Irwig L: The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58: 882-893, 2005.
21. Yang CT, Lee MH, Lan RS and Chen JK: Telomerase activity in pleural effusions: diagnostic significance. J Clin Oncol 16: 567-573, 1998.
22. Yang Z and Xie C: Comparison of the diagnostic value of telomerase activity with CEA level in benign and malignant pleural effusions. Zhonghua Jie He Hu Xi Za Zhi 24: 201-203, 2001 (In Chinese).
23. Dikmen G, Dikmen E, Kara M, Sahin E, Dogan P and Ozdemir N: Diagnostic implications of telomerase activity in pleural effusions. Eur Respir J 22: 422-426, 2003.
24. Lee WY: Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination. Cytodiagnosis 16: 227-232, 2005.
25. Manecheotswuan K, Lertworawiat A, Tscheikuna J and Wamanuttajinda V: Comparison of telomerase activity between malignant and tuberculous pleural effusions. J Med Assoc Thai 89: (Suppl 5) S46-54, 2006.
26. Li GB, Wang M, Guo S, Liu Y and Wang W: Value of combined pleural effusion test and CEA for differential diagnosis of malignant and nonmalignant pleural effusion. Chin J Cancer Prev Treat 15: 299-300, 318, 2008.
27. Mousavi SA, Bahari R and Karimi MA: Comparison of telomerase activity in malignant and benign pleural effusions. Dis Mon 52: 17-23, 2006.
28. Li H, Fu J, Xiu Y and Zhou Q: Diagnostic significance of combining telomerase activity with CYFRA21-1 level in differentiating malignant pleural effusion caused by lung cancer from benign pleural effusion. Zhongguo Fei Ai Za Zhi 13: 652-654, 2010 (In Chinese).
29. Walter SD: Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 21: 1237-1256, 2002.

EXPERIMENTAL AND THERAPEUTIC MEDICINE 4: 487-492, 2012

491
30. Jones CM and Athanasiou T: Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg 79: 16-20, 2005.

31. Glas AS, Lijmer JG, Prins MH, Bossuyt PM: The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 56: 1129-1135, 2003.

32. Stengel D, Bauwens K, Sehouli J, Ekkernkamp A and Porzsolt F: A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen 10: 47-51, 2003.

33. Hansson M, Zendehrokh N, Ohyashiki J, et al: Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay. Arch Pathol Lab Med 132: 1896-1902, 2008.

34. Dejmek A, Yahata N, Ohyashiki K, et al: In situ telomerase activity in pleural effusions: a promising marker for malignancy. Diagn Cytopathol 24: 11-15, 2001.

35. Song F, Khan KS, Dinnes J and Sutton AJ: Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 31: 88-95, 2002.